目的：探讨免疫抑制疗法（IST）对儿童再生障碍性贫血（AA）的疗效及其影响疗效的相关因素。方法：对2003年2月至2009年11月住院接受IST治疗的、可进行疗效评估的110例AA患儿的临床资料进行回顾性分析。110例患儿中，重型AA（SAA）83例，非重型 AA（非SAA）27例。前者采用抗胸腺细胞球蛋白（ATG）联合环孢素（CSA）及泼尼松、雄激素四联治疗，后者采用CSA联合泼尼松、雄激素三联治疗。结果：SAA与非SAA组的总有效率分别为69.9%和70.4%。单因素分析显示病程、骨髓CD34+细胞比例、CD4+CD25+调节性T细胞比例与疾病严重程度相关，但与预后无关。治疗有效组患儿年龄、病程、骨髓CD3+、CD8+细胞比例显著低于治疗无效组（P<0.05）。多因素分析显示年龄＞10岁、骨髓CD8+细胞比例＞25%的患儿治疗失败的风险分别是对应组的3.36倍和3.59倍。结论：IST治疗儿童AA疗效确切。年龄、病程、CD3+、CD8+ T细胞水平与IST的疗效相关。
Abstract
OBJECTIVE: To evaluate the effectiveness of immunosuppressive therapy (IST) for childhood aplastic anemia (AA) and its predictive factors. METHODS: The medical data of 110 children with AA who received IST between February 2003 and November 2009 were retrospectively studied. Of these patients, 83 were diagnosed as severe AA (SAA) and 27 were non-SAA. The former group was treated with antithymocyte globulin (ATG) + ciclosporin (CSA) +prednisone + androgens and the latter with CSA + prednisone + androgens. RESULTS: Total response rates in the SAA and non-SAA groups were 69.9% and 70.4%, respectively. Univariate analysis showed that disease duration, CD34+ cell level in bone marrow (BM) and the expression of CD4+CD25+ regulatory T cell in BM were related to the severity of disease but not correlated with treatment response. Age, disease duration and proportions of CD3+ and CD8+ T cells in BM were predictive factors for response to IST. Multivariate analysis revealed that patients aged more than 10 years and patients with a CD8+ cell proportion in BM of over 25% had hazard ratios of 3.36 and 3.59 for treatment failure respectively. CONCLUSIONS: IST is effective in the treatment of childhood AA. Age, disease duration and the proportion of CD8+ T cell in BM are predictive factors for response to IST.
关键词
再生障碍性贫血 /
免疫抑制治疗 /
抗胸腺细胞球蛋白 /
儿童
Key words
Aplastic anemia /
Immunosuppressive therapy /
Antithymocyte globulin /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］Passweg JR, Marsh JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation［J］. Hematology Am Soc Hematol Educ Program, 2010: 36-42.
［2］Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine［J］. J Pediatr, 2008, 153(6): 814-819.
［3］王颖超, 殷楚云, 冯磊, 王春美, 马丽娜, 魏永纬, 等.免疫抑制疗法治疗儿童再生障碍性贫血疗效分析［J］. 中国当代儿科杂志, 2012,14(1):33-37.
［4］Yoshida N, Yagasaki H, Hama A, Takahashi Y, Kosaka Y, Kobayashi R, et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia［J］. Haematologica, 2011, 96(5): 771-774.
［5］中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 小儿再生障碍性贫血的诊疗建议［J］. 中华儿科杂志, 2001,39(7):422-423.
［6］Li JP, Zheng CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia［J］. Crit Rev Oncol Hematol, 2010, 75(2): 79-93.
［7］王西阁, 曹祎明, 王晓格. CD4+CD25int/highCD127low调节性T细胞在再生障碍性贫血患儿中的检测及意义［J］. 中国当代儿科杂志, 2011,13(4):292-295.
［8］Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severeaplastic anemia［J］. Eur J Haematol, 2010, 84(2): 154-159.
［9］Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia［J］. Br J Haematol, 2009, 144(2): 206-216.
［10］Deyell RJ, Shereck EB, Milner RA, Schultz KR. Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia［J］. Pediatr Hematol Oncol, 2011, 28(6): 469-478.
［11］冯乐, 付蓉, 王化泉, 王珺, 刘春燕, 李丽娟, 等. 重型再生障碍性贫血患者CD8+效应T细胞损伤骨髓造血途径的研究［J］. 中华血液学杂志, 2011,32(9):597-601.
［12］邱奕宁, 白燕, 余慧, 周东风, 张志泉, 肖燕, 等. 大剂量丙种球蛋白与环孢素A治疗儿童再生障碍性贫血的疗效分析［J］. 中国当代儿科杂志, 2009,11(1):33-36.
PDF(1004 KB)
